1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Xanthine Oxidase

Xanthine Oxidase

XO

Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.

Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162961
    Xanthine oxidase-IN-16
    Inhibitor
    Xanthine oxidase-IN-16 is potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 102 nM. Xanthine oxidase-IN-16 shows significant efficacy in hyperuricemia rats.
    Xanthine oxidase-IN-16
  • HY-Y0106R
    2,6-Dihydroxyacetophenone (Standard)
    Inhibitor
    2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.
    2,6-Dihydroxyacetophenone (Standard)
  • HY-W039271
    2-Chloro-6-methoxypurine riboside
    2-Chloro-6-methoxypurine riboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
    2-Chloro-6-methoxypurine riboside
  • HY-N0196A
    Baicalein hydrate
    Inhibitor
    Baicalein hydrate (ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.
    Baicalein hydrate
  • HY-116433
    Nequinate
    Inhibitor
    Nequinate, a quinoline compound, is an anticoccidial agent against cecal coccidiosis (Eimeria tenella) infections. Nequinate inhibits xanthine oxidoreductase (XOD) activity.
    Nequinate
  • HY-N0778R
    Isorhamnetin-3-O-neohespeidoside (Standard)
    Inhibitor
    Isorhamnetin-3-O-neohespeidoside (Standard) is the analytical standard of Isorhamnetin-3-O-neohespeidoside (HY-N0778). This product is intended for research and analytical applications. Isorhamnetin-3-O-neohespeidoside is a flavonoid. Isorhamnetin-3-O-neohespeidoside can be isolated from Typha angustifolia. Isorhamnetin-3-O-neohespeidoside inhibits xanthine oxidase activity with an IC50 of 48.75 μg mL. Isorhamnetin-3-O-neohespeidoside has antioxidant and osteoclastogenic activities. Isorhamnetin-3-O-neohespeidoside can be used in research of bone.
    Isorhamnetin-3-O-neohespeidoside (Standard)
  • HY-154017
    2′-C-Methyl-6-O-methylinosine
    2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
    2′-C-Methyl-6-O-methylinosine
  • HY-N9324
    Ilexoside O
    Inhibitor
    Ilexoside O is a triterpene saponin isolated from the roots of Ilex pubescens. Ilexoside O exhibits weak xanthine oxidase (XOD) inhibitory activity (IC50=53.05 μM).
    Ilexoside O
  • HY-162882
    CC15009
    Inhibitor
    CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates.
    CC15009
  • HY-129889
    Febuxostat acyl glucuronide
    Inhibitor
    Febuxostat acyl glucuronide (Febuxostat acyl-β-D-glucuronide) is a metabolite of Febuxostat (HY-14268). Febuxostat is a potent, selective and non-purine xanthine oxidase (XO) inhibitor.
    Febuxostat acyl glucuronide
  • HY-N7150
    Tricetin 3',4',5'-trimethyl ether
    Inhibitor
    Tricetin 3',4',5'-trimethyl ether (5,7-Dihydroxy-3',4',5'-trimethoxyflavone) is a flavone glucoside, that can be isolated the flowers of Chrysanthemum sinensea. Tricetin 3',4',5'-trimethyl ether displays xanthine oxidase competitive-type inhibitory activity, with an IC50 of 0.51 μM and a Ki of 0.37 μM.
    Tricetin 3',4',5'-trimethyl ether
  • HY-N3906
    Fraxamoside
    Inhibitor
    Fraxamoside is a competitive xanthine oxidase inhibitor with an IC50 of 16.1 μM and a Ki of 0.9 μM.
    Fraxamoside
  • HY-N10863
    Aurantiamide benzoate
    Inhibitor
    Aurantiamide benzoate is a nature product that could be isolated from two tropical medicinal plants, Cunila spicata and Hyptis fasciculata. Aurantiamide benzoate is a potent xanthine oxidase inhiobitor with an IC50 value of 70 μM.
    Aurantiamide benzoate
  • HY-151973
    Xanthine oxidoreductase-IN-3
    Inhibitor
    Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia.
    Xanthine oxidoreductase-IN-3
  • HY-144456
    Xanthine oxidase-IN-5
    Inhibitor
    Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
    Xanthine oxidase-IN-5
  • HY-W699983
    Imidazole-15N2
    Imidazole-15N2 (Glyoxaline-15N2) is 15N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease.
    Imidazole-<sup>15</sup>N<sub>2</sub>
  • HY-N7397
    Forsythoside F
    Inhibitor
    Forsythoside F (Arenarioside) is a xanthine oxidase inhibitor and possesses antihyperuricemic effects in vivo.
    Forsythoside F
  • HY-175303
    Xanthine oxidase-IN-17
    Inhibitor
    Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 298 nM and a Ki of 167 nM. Xanthine oxidase-IN-17 decreases the formation of O radical by inhibiting the catalytic activity of XOD to diminish the production of uric acid. Xanthine oxidase-IN-17 shows no cytotoxicity in AML-12 hepatocytes, while suppressing uric acid production. Xanthine oxidase-IN-17 can be used for the studies of hyperuricemia and subsequently to gout.
    Xanthine oxidase-IN-17
  • HY-156360
    Xanthine oxidase-IN-12
    Inhibitor
    Xanthine oxidase-IN-12 (Compound 11) is a xanthine oxidase (XO) inhibitor with an IC50 of 91 nM. Xanthine oxidase-IN-12 also has antioxidant activity and reduces intracellular ROS.
    Xanthine oxidase-IN-12
  • HY-161523
    XOR/URAT1-IN-1
    Inhibitor
    XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model.
    XOR/URAT1-IN-1
Cat. No. Product Name / Synonyms Application Reactivity